Article

SARcode reports phase III results for lifitegrast

SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Related Content
From eye care to cancer care: Expanding role of OCT imaging
November 27th 2024

From eye care to cancer care: Expanding role of OCT imaging

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Microglial activation in AMD: Hyperreflective retinal foci offer insights for disease progression and monitoring
November 27th 2024

Microglial activation in AMD: Hyperreflective retinal foci offer insights for disease progression and monitoring

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

Study examines efficiency of physiotherapy in treating, preventing uncomplicated acquired myopia
November 26th 2024

Study examines efficiency of physiotherapy in treating, preventing uncomplicated acquired myopia

Researchers find new model of neuronal circuit provides insight on eye movement
November 26th 2024

Researchers find new model of neuronal circuit provides insight on eye movement

© 2024 MJH Life Sciences

All rights reserved.